X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21291) 21291
Newsletter (455) 455
Newspaper Article (47) 47
Book Chapter (32) 32
Magazine Article (29) 29
Dissertation (12) 12
Conference Proceeding (11) 11
Publication (6) 6
Book / eBook (5) 5
Book Review (2) 2
Reference (1) 1
Streaming Video (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14132) 14132
pseudomonas aeruginosa (6636) 6636
pseudomonas infections - drug therapy (6405) 6405
male (6032) 6032
female (5753) 5753
pseudomonas-aeruginosa (5736) 5736
microbiology (5421) 5421
pseudomonas aeruginosa - drug effects (4906) 4906
anti-bacterial agents - therapeutic use (4784) 4784
anti-bacterial agents - pharmacology (4267) 4267
antibiotics (4158) 4158
animals (4000) 4000
microbial sensitivity tests (3853) 3853
adult (3756) 3756
infectious diseases (3751) 3751
middle aged (3381) 3381
pharmacology & pharmacy (3362) 3362
bacteria (3351) 3351
infections (3285) 3285
aged (2700) 2700
pseudomonas infections - microbiology (2617) 2617
pseudomonas aeruginosa - isolation & purification (2335) 2335
cystic fibrosis (2308) 2308
health aspects (2184) 2184
research (2106) 2106
infection (2014) 2014
adolescent (1965) 1965
anti-bacterial agents - administration & dosage (1940) 1940
drug resistance (1913) 1913
child (1818) 1818
drug resistance in microorganisms (1712) 1712
mice (1690) 1690
resistance (1689) 1689
escherichia-coli (1634) 1634
biofilms (1615) 1615
pathogens (1550) 1550
research article (1432) 1432
treatment outcome (1429) 1429
respiratory system (1404) 1404
analysis (1397) 1397
antimicrobial agents (1386) 1386
bacterial infections - drug therapy (1362) 1362
immunology (1360) 1360
drug resistance, bacterial (1332) 1332
risk factors (1330) 1330
therapy (1268) 1268
gram-negative bacteria (1254) 1254
pneumonia (1199) 1199
drug resistance, multiple, bacterial (1196) 1196
cystic fibrosis - complications (1170) 1170
mortality (1168) 1168
drug resistance, microbial (1164) 1164
staphylococcus-aureus (1136) 1136
drug therapy, combination (1118) 1118
bacterial infections (1113) 1113
virulence (1107) 1107
retrospective studies (1101) 1101
care and treatment (1087) 1087
biofilms - drug effects (1086) 1086
medicine (1064) 1064
pseudomonas infections - complications (1058) 1058
pseudomonas (1053) 1053
child, preschool (1048) 1048
cystic-fibrosis (1020) 1020
in-vitro (1003) 1003
staphylococcal infections - drug therapy (1003) 1003
antibiotic resistance (1000) 1000
nosocomial infections (992) 992
epidemiology (979) 979
antimicrobial resistance (976) 976
escherichia coli - drug effects (974) 974
drug therapy (962) 962
staphylococcus aureus - drug effects (954) 954
pseudomonas aeruginosa - genetics (949) 949
cystic fibrosis - microbiology (946) 946
antibacterial agents (910) 910
bacteria - drug effects (896) 896
biofilm (892) 892
disease models, animal (877) 877
infant (870) 870
cross infection - drug therapy (867) 867
ciprofloxacin (865) 865
cross infection - microbiology (865) 865
aged, 80 and over (853) 853
cystic fibrosis - drug therapy (835) 835
multidisciplinary sciences (831) 831
hospitals (828) 828
time factors (813) 813
biochemistry & molecular biology (805) 805
biochemical phenomena, metabolism, and nutrition (803) 803
medicine, general & internal (794) 794
surgery (790) 790
antibiotic-resistance (779) 779
pseudomonas infections - etiology (778) 778
risk-factors (777) 777
urinary tract infections - drug therapy (758) 758
pediatrics (750) 750
pseudomonas aeruginosa - pathogenicity (742) 742
pseudomonas aeruginosa - physiology (741) 741
ventilator-associated pneumonia (740) 740
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (20463) 20463
Japanese (434) 434
German (382) 382
French (286) 286
Spanish (207) 207
Russian (206) 206
Italian (120) 120
Portuguese (81) 81
Polish (60) 60
Chinese (59) 59
Romanian (30) 30
Turkish (24) 24
Czech (17) 17
Danish (13) 13
Dutch (11) 11
Hungarian (9) 9
Hebrew (7) 7
Norwegian (7) 7
Croatian (6) 6
Ukrainian (6) 6
Lithuanian (4) 4
Persian (4) 4
Swedish (3) 3
Afrikaans (2) 2
Slovak (2) 2
Arabic (1) 1
Bosnian (1) 1
Bulgarian (1) 1
Korean (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of infection, ISSN 0163-4453, 2014, Volume 69, Issue 3, pp. 216 - 225
Summary Background An intervention for Gram-negative bloodstream infections that integrated mass spectrometry technology for rapid diagnosis with antimicrobial stewardship oversight significantly... 
Infectious Disease | Bloodstream infections | Multidrug resistant | Antimicrobial stewardship | MALDI-TOF | Rapid diagnostics | MORTALITY | ACQUIRED INFECTIONS | INFECTIOUS DISEASES | METAANALYSIS | IDENTIFICATION | DISEASES SOCIETY | IMPACT | THERAPY | HEALTH-CARE | BLOOD-STREAM INFECTIONS | ENTEROBACTERIACEAE | Humans | Middle Aged | Bacteremia - mortality | Male | Pseudomonas Infections - mortality | Gram-Negative Bacterial Infections - microbiology | Time Factors | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Escherichia coli Infections - drug therapy | Escherichia coli - enzymology | Time-to-Treatment | Bacteremia - drug therapy | Klebsiella - enzymology | Gram-Negative Bacterial Infections - drug therapy | Pseudomonas Infections - diagnosis | Survival Rate | Pseudomonas Infections - microbiology | Klebsiella Infections - diagnosis | Gram-Negative Bacterial Infections - diagnosis | Hospital Costs | Escherichia coli Infections - mortality | Pseudomonas aeruginosa - isolation & purification | beta-Lactam Resistance | Acinetobacter Infections - mortality | Klebsiella - isolation & purification | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Resistance, Multiple, Bacterial | Acinetobacter baumannii - isolation & purification | Adult | Female | beta-Lactamases - metabolism | Acinetobacter Infections - microbiology | Length of Stay | Escherichia coli Infections - diagnosis | Intensive Care Units | Klebsiella Infections - drug therapy | Acinetobacter Infections - diagnosis | Hospital Mortality | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Treatment Outcome | Bacteremia - diagnosis | Klebsiella Infections - microbiology | Escherichia coli - isolation & purification | Klebsiella Infections - mortality | Aged | Gram-Negative Bacterial Infections - mortality | Drug resistance in microorganisms | Care and treatment | Mass spectrometry | Patient outcomes
Journal Article
Burns, ISSN 0305-4179, 2017, Volume 43, Issue 3, pp. 642 - 653
Highlights • Burn depth/agent increases risk of developing an infection. • Infections found folliculitis, burn wound, urinary tract, pneumonia, CVC and bloodstream... 
Critical Care | Nosocomial infection | Burn wound infection | Pneumonia | Urinary tract infection | Health care related infection | Burns | URINARY-TRACT-INFECTION | MORTALITY | SURGERY | RISK-FACTORS | DERMATOLOGY | REPLACEMENT | BACTERIOLOGY | CATHETERS | INTENSIVE-CARE-UNIT | SURVEILLANCE | ASSOCIATION | BLOOD-STREAM INFECTIONS | CRITICAL CARE MEDICINE | Escherichia coli | Humans | Middle Aged | Child, Preschool | Male | Young Adult | Folliculitis - epidemiology | Aged, 80 and over | Urinary Tract Infections - microbiology | Catheter-Related Infections - epidemiology | Child | Infant, Newborn | Staphylococcus aureus | Escherichia coli Infections - drug therapy | Bacteremia - drug therapy | Pseudomonas Infections - microbiology | Wound Infection - epidemiology | Catheter-Related Infections - drug therapy | Drug Resistance, Microbial | Escherichia coli Infections - epidemiology | Acinetobacter baumannii | Catheter-Related Infections - microbiology | Adolescent | Bacteremia - epidemiology | Infant | Bacteremia - microbiology | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Adult | Female | Pseudomonas aeruginosa | Staphylococcal Infections - microbiology | Wound Infection - drug therapy | Acinetobacter Infections - microbiology | Staphylococcal Infections - drug therapy | Colombia - epidemiology | Klebsiella Infections - drug therapy | Central Venous Catheters | Pneumonia - epidemiology | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Folliculitis - microbiology | Pneumonia - microbiology | Klebsiella Infections - microbiology | Oxacillin - therapeutic use | Burns - epidemiology | Urinary Tract Infections - drug therapy | Urinary Tract Infections - epidemiology | Pneumonia - drug therapy | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Acinetobacter Infections - epidemiology | Wound Infection - microbiology | Aged | Folliculitis - drug therapy | Klebsiella pneumoniae | Development and progression | Burns and scalds | Surgery, Plastic | Health aspects | Staphylococcus aureus infections | Analysis | Bacterial pneumonia | Mortality | Urinary tract infections | Bacteria | Disease susceptibility | Antibacterial agents
Journal Article
The Journal of infectious diseases, ISSN 1537-6613, 2014, Volume 210, Issue 9, pp. 1357 - 1366
Background. Limitations in treatment of biofilm-associated bacterial infections are often due to subpopulation of persistent bacteria (persisters... 
Biofilms | Antibiotics | Escherichia coli | Bacteria | Aminoglycosides | Pseudomonas aeruginosa | Infections | Basic amino acids | Staphylococcus aureus | aminoglycoside | persister | catheter-related infections | biofilm | proton motive force | DIAGNOSIS | INFECTIOUS DISEASES | INFECTIONS | MANAGEMENT | TOLERANCE | SUSCEPTIBILITY | MICROBIOLOGY | IMMUNOLOGY | ANTIBIOTIC-LOCK THERAPY | GENTAMICIN | PSEUDOMONAS-AERUGINOSA | L-ARGININE | GROWTH | Escherichia coli Infections - prevention & control | Central Venous Catheters - microbiology | Escherichia coli - drug effects | Gentamicins - administration & dosage | Catheter-Related Infections - prevention & control | Pseudomonas Infections - prevention & control | Arginine - administration & dosage | Gentamicins - pharmacology | Drug Therapy, Combination | Biofilms - drug effects | Escherichia coli Infections - drug therapy | Staphylococcal Infections - drug therapy | Pseudomonas Infections - drug therapy | Rats | Central Venous Catheters - adverse effects | Pseudomonas aeruginosa - drug effects | Catheter-Related Infections - drug therapy | Drug Synergism | Animals | Arginine - pharmacology | Staphylococcal Infections - prevention & control | Anti-Bacterial Agents - pharmacology | In Vitro Techniques | Staphylococcus aureus - drug effects | Hydrogen-Ion Concentration | Health aspects | Research | Index Medicus | Abridged Index Medicus | Biofilms/drug effects | Gentamicins/administration & dosage | Anti-Bacterial Agents/pharmacology | Staphylococcal Infections/drug therapy | Arginine/administration & dosage | Life Sciences | Escherichia coli Infections/drug therapy | Staphylococcus aureus/drug effects | Gentamicins/pharmacology | Catheter-Related Infections/prevention & control | Pseudomonas aeruginosa/drug effects | Staphylococcal Infections/prevention & control | Catheter-Related Infections/drug therapy | Central Venous Catheters/microbiology | Escherichia coli/drug effects | Bacteriology | Microbiology and Parasitology | Central Venous Catheters/adverse effects | Arginine/pharmacology | Pseudomonas Infections/prevention & control | Escherichia coli Infections/prevention & control | Pseudomonas Infections/drug therapy
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2016, Volume 16, Issue 6, pp. 661 - 673
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 3, p. e91713
...) in a network of community hospitals and 2) determine risk factors for inappropriate therapy for bloodstream infections in community hospitals... 
METHICILLIN-RESISTANT | MORTALITY | METAANALYSIS | MULTIDISCIPLINARY SCIENCES | ANTIMICROBIAL TREATMENT | VALIDATION | PREVENTION | STAPHYLOCOCCUS-AUREUS BACTEREMIA | ENDOCARDITIS | EPIDEMIOLOGY | SEVERITY | United States - epidemiology | Pseudomonas aeruginosa - isolation & purification | Community-Acquired Infections - epidemiology | Escherichia coli - drug effects | Humans | Middle Aged | Pseudomonas aeruginosa - growth & development | Drug Resistance, Bacterial | Male | Hospitals, Community | Bacteremia - microbiology | Gram-Negative Bacterial Infections - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Female | Retrospective Studies | Staphylococcal Infections - microbiology | Escherichia coli - growth & development | Cross Infection - epidemiology | Medication Errors | Staphylococcal Infections - drug therapy | Staphylococcus aureus - isolation & purification | Bacteremia - drug therapy | Gram-Negative Bacterial Infections - drug therapy | Pseudomonas aeruginosa - drug effects | Cross Infection - drug therapy | Staphylococcal Infections - epidemiology | Escherichia coli - isolation & purification | Cross Infection - microbiology | Gram-Negative Bacterial Infections - epidemiology | Bacteremia - epidemiology | Aged | Staphylococcus aureus - drug effects | Staphylococcus aureus - growth & development | Community-Acquired Infections - microbiology | Health care | Therapy | Pediatrics | Communities | Physicians | Infections | Drug resistance | Epidemiology | Antiinfectives and antibacterials | Risk factors | Data dictionaries | 21st century | E coli | Trends | Nosocomial infections | Medical personnel | Pathogens | Coagulase | Comorbidity | Mortality | Staphylococcus infections | Antimicrobial agents | Risk analysis | Patients | Disease control | Studies | Infectious diseases | Hospitals | Endocarditis
Journal Article
PloS one, ISSN 1932-6203, 2017, Volume 12, Issue 4, p. e0176883
.... QS-controlled biofilm formation by Pseudomonas aeruginosa in clinical settings has remained controversial due to emerging drug resistance... 
IN-VITRO | TWITCHING MOTILITY | TO-CELL COMMUNICATION | SYNERGISTIC ANTIBACTERIAL EFFICACY | EARLY COMBINATION TREATMENT | MULTIDISCIPLINARY SCIENCES | SUSCEPTIBILITY | IV PILI | CYSTIC-FIBROSIS | LUNG INFECTION | BACTERIAL BIOFILMS | Virulence - drug effects | Prostheses and Implants - microbiology | Pseudomonas aeruginosa - physiology | Interferon-gamma - metabolism | Prosthesis-Related Infections - drug therapy | Dose-Response Relationship, Drug | Pseudomonas Infections - metabolism | Prosthesis-Related Infections - microbiology | Pseudomonas aeruginosa - pathogenicity | Female | Flavonoids - pharmacology | Drug Therapy, Combination | Disease Models, Animal | Biofilms - drug effects | Quorum Sensing - drug effects | Pseudomonas Infections - drug therapy | Interleukin-4 - metabolism | Pseudomonas aeruginosa - drug effects | Pseudomonas Infections - microbiology | Caenorhabditis elegans | Animals | Bacterial Proteins - metabolism | Prosthesis-Related Infections - metabolism | Virulence Factors - metabolism | Anti-Bacterial Agents - pharmacology | Mice, Inbred BALB C | Pseudomonas aeruginosa - ultrastructure | Peritoneum | Usage | Physiological aspects | Pseudomonas aeruginosa | Quorum sensing | Medicine, Chinese | Research | Virulence (Microbiology) | Surgical implants | Motility | Transplants & implants | Genes | Virulence | Inflammatory response | Infections | Drug resistance | Chinese medicine | Bacteria | Life sciences | Elastase | Nosocomial infections | Immune system | Pathogens | Immune response | Mortality | Staphylococcus infections | Cystic fibrosis | Gene expression | Mitigation | Biofilms | Hospitals | Antibiotics | Respiratory diseases | Nematodes | Mice | Infiltration | Interferon | In vitro methods and tests
Journal Article
PloS one, ISSN 1932-6203, 12/2016, Volume 11, Issue 12, p. e0167522
In this study, we retrospectively reviewed the clinical experience of patients receiving doripenem-containing regimens for the treatment of healthcare-associated infections (HCAIs... 
IN-VITRO | MULTICENTER | BACTERIAL-INFECTIONS | IMIPENEM-CILASTATIN | EFFICACY | VENTILATOR-ASSOCIATED PNEUMONIA | SAFETY | PSEUDOMONAS-AERUGINOSA | MULTIDISCIPLINARY SCIENCES | SURVEILLANCE | ANTIMICROBIAL ACTIVITY | Soft Tissue Infections - mortality | Urinary Tract Infections - mortality | Humans | Middle Aged | Cross Infection - mortality | Male | Tertiary Care Centers - statistics & numerical data | Hospital Mortality - trends | Respiratory Tract Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Cross Infection - pathology | Respiratory Tract Infections - mortality | Soft Tissue Infections - pathology | Aged, 80 and over | Female | Urinary Tract Infections - microbiology | Urinary Tract Infections - pathology | Retrospective Studies | Soft Tissue Infections - drug therapy | Respiratory Tract Infections - pathology | Intraabdominal Infections - microbiology | Respiratory Tract Infections - drug therapy | Treatment Outcome | Cross Infection - drug therapy | Urinary Tract Infections - drug therapy | Intraabdominal Infections - mortality | Intraabdominal Infections - pathology | Soft Tissue Infections - microbiology | Carbapenems - therapeutic use | Cross Infection - microbiology | Aged | Intraabdominal Infections - drug therapy | APACHE | Infection | Doripenem | Care and treatment | Dosage and administration | Health care | Therapy | Pneumonia | Intensive care | Health services | Medical records | Infections | Urinary tract | Drug resistance | Respiratory tract | Respiratory tract diseases | Urinary tract infections | Urogenital system | Pathogens | Ventilators | Medical research | Statistical analysis | Bacterial infections | Review boards | Mortality | Antimicrobial agents | Patients | Abdomen | Urinary tract diseases | Medicine | Studies | Hospitals | Antibiotics | Pharmacy | Skin | Adults
Journal Article
PloS one, ISSN 1932-6203, 11/2015, Volume 10, Issue 11, p. e0139686
The administration of prebiotics as oligosaccharides (OS), by acting on intestinal microbiota, could modulate the immune and inflammatory response and represent a new strategy to improve the outcome of bacterial infection... 
IMMUNE-RESPONSE | CELLS | ACTIVATION | CHAIN FATTY-ACIDS | BIFIDOBACTERIA | MULTIDISCIPLINARY SCIENCES | MONOCYTES | GALACTO-OLIGOSACCHARIDES | BUTYRATE | MICROBIOTA | POLARIZATION | Lung Diseases - microbiology | Pseudomonas Infections - drug therapy | Mice, Inbred C57BL | Oligosaccharides - therapeutic use | Pseudomonas Infections - complications | Male | Treatment Outcome | Pneumonia - microbiology | Lung Diseases - drug therapy | Pseudomonas Infections - microbiology | Fatty Acids, Volatile - metabolism | Pectins - chemistry | Pseudomonas Infections - immunology | Lung Diseases - immunology | Animals | Feces - chemistry | Pneumonia - drug therapy | Diet | Bacterial Load - immunology | Survival Analysis | Pneumonia - complications | Pneumonia - immunology | Pseudomonas aeruginosa | Lung Diseases - complications | Pseudomonas aeruginosa infections | Care and treatment | Oligosaccharides | Health aspects | Lung diseases | Inflammatory response | Infections | Lymphocytes T | Macrophages | Butyric acid | Recruitment | Microbiota | Interleukin 4 | Intestine | Bacteria | Tumor necrosis factor-TNF | Intestinal microflora | Immune response | Bacterial infections | Cytokines | Cystic fibrosis | Pectin | Inflammation | Prebiotics | Lungs | Antibiotics | γ-Interferon | Interleukin 10 | Mice | Interferon | Laboratory animals | Pseudomonas Infections/microbiology | Pneumonia/microbiology | Pneumonia/drug therapy | Lung Diseases/immunology | Lung Diseases/microbiology | Life Sciences | Pseudomonas Infections/complications | Pseudomonas Infections/immunology | Lung Diseases/complications | Food and Nutrition | Feces/chemistry | Lung Diseases/drug therapy | Pulmonology and respiratory tract | Pneumonia/complications | Oligosaccharides/therapeutic use | Fatty Acids, Volatile/metabolism | Human health and pathology | Infectious diseases | Pneumonia/immunology | Pectins/chemistry | Pseudomonas Infections/drug therapy | Bacterial Load/immunology
Journal Article